Zuellig Pharma and Regeneron sign deal to supply Libtayo in South Korea and Taiwan
Zuellig Pharma has entered into an exclusive distribution agreement with Regeneron Ireland DAC for the launch and commercialisation of Libtayo (cemiplimab) in the South Korean and Taiwanese markets. A fully human monoclonal antibody, Libtayo acts on the …